• Subscribe
  • Magazine
  • Past Issues
  • Surveys
  • Industry Statistics
  • About Us
  • Members Only
  • Best Places to Work
    • Recent Quotes
    My Watchlist
    Indicators
    PennEnergy Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    bioAffinity Technologies, Inc. - Warrant (NQ: BIAFW )

    1.590 -0.140 (-8.09%)
    Streaming Delayed Price Updated: 3:55 PM EDT, Aug 23, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 18,947
    Open 1.700
    Bid (Size) 1.010 (1)
    Ask (Size) 1.760 (4)
    Prev. Close 1.730
    Today's Range 1.500 - 2.250
    52wk Range 0.0460 - 2.900
    Shares Outstanding N/A
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    bioAffinity Technologies CFO to Depart for New Opportunity; J. Michael Edwards to Return as Interim CFO
    From bioAffinity Technologies, Inc.
    Via Business Wire
    bioAffinity Technologies Reports $2.4 Million Revenue for Q2 Driven by Growing CyPath® Lung Sales
    From bioAffinity Technologies, Inc.
    Via Business Wire

    Performance

    YTD
    +1314.59%
    +1314.59%
    1 Month
    +117.84%
    +117.84%
    3 Month
    +657.14%
    +657.14%
    6 Month
    +695.00%
    +695.00%
    1 Year
    +448.28%
    +448.28%

    More News

    Read More
    bioAffinity Technologies Announces Closing of Registered Direct Offering, Concurrent Private Placement and Warrant Inducement for Aggregate Gross Proceeds of $1.75 Million
    From bioAffinity Technologies, Inc.
    Via Business Wire
    bioAffinity Technologies Announces Pricing of Registered Direct Offering and Concurrent Private Placement and Warrant Inducement for Aggregate Gross Proceeds of $1.75 Million
    From bioAffinity Technologies, Inc.
    Via Business Wire
    bioAffinity Technologies Reports 217% Sales Growth in Second Quarter 2024 for CyPath® Lung
    From bioAffinity Technologies, Inc.
    Via Business Wire
    bioAffinity Technologies Reports Accelerating Growth of Physician Practices Ordering CyPath® Lung Tests
    From bioAffinity Technologies, Inc.
    Via Business Wire
    bioAffinity Technologies Reports Record Q1 Revenue Driven by Accelerating Growth of CyPath® Lung Sales and Increased Laboratory Volumes
    From bioAffinity Technologies, Inc.
    Via Business Wire
    bioAffinity Technologies News Update
    From bioAffinity Technologies, Inc.
    Via Business Wire
    bioAffinity Technologies Advances New Product Development Initiatives to Accelerate Next Phase of Growth
    From bioAffinity Technologies, Inc.
    Via Business Wire
    bioAffinity Technologies Expands Campaign to Support American Cancer Society Initiative for Lung Cancer Screening
    From bioAffinity Technologies, Inc.
    Via Business Wire
    bioAffinity Technologies Reports Fourth Quarter and Full Year 2023 Financial Results
    From bioAffinity Technologies, Inc.
    Via Business Wire
    bioAffinity Technologies Announces Closing of $2.5 Million Registered Direct Offering and Concurrent Private Placement
    From bioAffinity Technologies, Inc.
    Via Business Wire
    bioAffinity Technologies Announces Pricing of $2.5 Million Registered Direct Offering and Concurrent Private Placement
    From bioAffinity Technologies, Inc.
    Via Business Wire
    bioAffinity Technologies News Update
    From bioAffinity Technologies, Inc.
    Via Business Wire
    bioAffinity Technologies In The News
    From bioAffinity Technologies, Inc.
    Via Business Wire
    bioAffinity Technologies In the News
    From bioAffinity Technologies
    Via Business Wire
    bioAffinity Technologies Appoints Jamie Platt, Ph.D., to its Board of Directors
    From bioAffinity Technologies, Inc.
    Via Business Wire
    CMS Posts Final Payment Determination for bioAffinity Technologies’ CyPath® Lung Effective January 2024
    From bioAffinity Technologies, Inc.
    Via Business Wire
    bioAffinity Technologies VP David Elzi, Ph.D., Named to American Society for Cell Biology Post
    From bioAffinity Technologies, Inc.
    Via Business Wire
    bioAffinity Technologies Reports Third Quarter 2023 Financial Results and Provides Business Update
    From bioAffinity Technologies, Inc.
    Via Business Wire
    bioAffinity Technologies Names Dallas J. Coleman as National Director of Sales
    From bioAffinity Technologies, Inc.
    Via Business Wire
    bioAffinity Technologies to Present at the 8th Annual Dawson James Small Cap Growth Conference
    From bioAffinity Technologies, Inc.
    Via Business Wire
    bioAffinity Technologies to Participate in the H.C. Wainwright Global Investment Conference
    From bioAffinity Technologies, Inc.
    Via Business Wire
    bioAffinity Technologies Reports Second Quarter 2023 Financial Results and Provides Business Update
    From bioAffinity Technologies, Inc.
    Via Business Wire
    AMA Issues CPT Code for bioAffinity Technologies’ CyPath® Lung Test for Early-Stage Lung Cancer
    From bioAffinity Technologies, Inc.
    Via Business Wire
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.